無料プレビュー

Regeneron Pharmaceuticals, Inc. (REGN) · NASDAQ Global Select

プロフィール

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA HD and EYLEA for ophthalmology, Dupixent for immunology and inflammation, Libtayo for solid organ oncology, Praluent for cardiovascular disease, and several others, distributed globally through its own comm

主要指標

株価: $737.83 (-0.58%)
時価総額: 760億ドル
PER（今期予想）: 13.0
PBR: 2.4
配当利回り: 0.50%
52週レンジ: $541.00 – $859.34
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: S&P 500 0.11% · Nasdaq 100 0.30%

比較会社: NVS Novartis AG、AZN AstraZeneca PLC、AMGN Amgen Inc.、GILD Gilead Sciences, Inc.、VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、ARGX argenx SE、SGEN Seagen Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-10-30 · 更新: 2026-10-08